There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvectis Pharma (NVCT – Research Report) and Invivyd (IVVD – Research Report) with bullish sentiments.
Nuvectis Pharma (NVCT)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma today and set a price target of $21.00. The company’s shares closed last Monday at $7.78, close to its 52-week low of $6.20.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Currently, the analyst consensus on Nuvectis Pharma is a Moderate Buy with an average price target of $21.00.
See the top stocks recommended by analysts >>
Invivyd (IVVD)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Invivyd today and set a price target of $15.00. The company’s shares closed last Monday at $3.10.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
Invivyd has an analyst consensus of Strong Buy, with a price target consensus of $11.33, which is a 241.3% upside from current levels. In a report issued on March 26, Morgan Stanley also upgraded the stock to Buy with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVCT:
- Nuvectis Pharma’s NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Inc trading resumes
- Nuvectis Pharma Inc trading halted, volatility trading pause
